Chlamydia trachomatis

Chlamydia trachomatis Overview

Chlamydia trachomatis is the most common bacterial STI, often asymptomatic but capable of causing infertility and pelvic inflammatory disease if untreated. Its inclusion in STI panels ensures early detection and treatment to prevent complications and transmission (USPSTF 2021, Workowski et al. 2021).

References

US Preventive Services Task Force, Davidson, K. W., Barry, M. J., Mangione, C. M., Cabana, M., Caughey, A. B., Davis, E. M., Donahue, K. E., Doubeni, C. A., Krist, A. H., Kubik, M., Li, L., Ogedegbe, G., Pbert, L., Silverstein, M., Simon, M. A., Stevermer, J., Tseng, C. W., & Wong, J. B. (2021). Screening for Chlamydia and Gonorrhea: US Preventive Services Task Force Recommendation StatementJAMA326(10), 949–956.

Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park I., Reno, H., Jonathan M. Zenilman J.M.,Bolan, G. A. (2021). Sexually transmitted infections treatment guidelines, 2021. MMWR Recommendations and Reports, 70(4), 1–187.

Products used to detect Chlamydia trachomatis

The STI large PCR panel is designed for multiplex in vitro assessment of 9 common microbiota typically associated with transmission by sexual activity, using real-time PCR.
The women’s health large PCR panel is designed for multiplex in vitro assessment of 37 common vaginal microbiota and resistance markers, using real-time PCR.